Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (<i>R</i>)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (PF-06821497)Pei‐Pei Kung, Martin P. Edwards, Ya‐Li Deng et al.|Journal of Medicinal Chemistry|2017Cited by 128
CCDC 1982336: Experimental Crystal Structure DeterminationPei‐Pei Kung, Martin P. Edwards, Patrick Bingham et al.|The Cambridge Structural Database|2020Cited by 0